Fiche société
Praxis Precision Medicines
Traitements, essais et publications liés.
Traitements17programmes
Essais5liés
Publications8liées
SourceDBlocale
Traitements
17| Molécule | Indication / population | Phase | Objectif | Pays | Résultat |
|---|---|---|---|---|---|
| 0.5mg elsunersenA Multi-Center, Single-Arm Clinical Trial to Investigate the Efficacy and Safety of Elsunersen in Pediatric Participants with Early Onset SCN2A Developmental and Epileptic Encephalopathy | Épilepsie | Phase 3 | À vérifier | United States, Brazil, Germany, Italy | À vérifier |
| 1.0mg/kg/day PRAX-562A Phase 3, Randomized, Multi-Center, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Relutrigine in Participants with Developmental and Epileptic Encephalopathies Followed by an Open-Label Extension | Épilepsie | Phase 3 | À vérifier | United States, Australia, Brazil | À vérifier |
| 1.5mg/kg/day PRAX-562A Phase 3, Randomized, Multi-Center, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Relutrigine in Participants with Developmental and Epileptic Encephalopathies Followed by an Open-Label Extension | Épilepsie | Phase 3 | À vérifier | United States, Australia, Brazil | À vérifier |
| 1mg elsunersenA Multi-Center, Single-Arm Clinical Trial to Investigate the Efficacy and Safety of Elsunersen in Pediatric Participants with Early Onset SCN2A Developmental and Epileptic Encephalopathy | Épilepsie | Phase 3 | À vérifier | United States, Brazil, Germany, Italy | À vérifier |
| 20 mg/day vormatrogine for 12 weeksA multicenter, double-blind, randomized, placebo-controlled clinical trial to evaluate the efficacy and safety of vormatrigine in adults with focal seizures (POWER2) | Épilepsie | Phase 3 | À vérifier | United States | À vérifier |
| 30 mg/day vormatrogine for 12 weeksA multicenter, double-blind, randomized, placebo-controlled clinical trial to evaluate the efficacy and safety of vormatrigine in adults with focal seizures (POWER2) | Épilepsie | Phase 3 | À vérifier | United States | À vérifier |
| 40 mg/day vormatrogine for 12 weeksA multicenter, double-blind, randomized, placebo-controlled clinical trial to evaluate the efficacy and safety of vormatrigine in adults with focal seizures (POWER2) | Épilepsie | Phase 3 | À vérifier | United States | À vérifier |
| PRAX-222 - Fixed DosesThe goal of this trial is to learn about the effect of PRAX-222 in pediatric participants with early onset SCN2A developmental and epileptic encephalopathy (DEE), aged 2 to 18 years. | Épilepsie | Phase 1/2 | À vérifier | United States, Brazil | À vérifier |
| PRAX-222 - Initial Ascending DosesThe goal of this trial is to learn about the effect of PRAX-222 in pediatric participants with early onset SCN2A developmental and epileptic encephalopathy (DEE), aged 2 to 18 years. | Épilepsie | Phase 1/2 | À vérifier | United States, Brazil | À vérifier |
| PRAX-222 - Initial DoseThe goal of this trial is to learn about the effect of PRAX-222 in pediatric participants with early onset SCN2A developmental and epileptic encephalopathy (DEE), aged 2 to 18 years. | Épilepsie | Phase 1/2 | À vérifier | United States, Brazil | À vérifier |
| PRAX-222 - Optional Ascending DosesThe goal of this trial is to learn about the effect of PRAX-222 in pediatric participants with early onset SCN2A developmental and epileptic encephalopathy (DEE), aged 2 to 18 years. | Épilepsie | Phase 1/2 | À vérifier | United States, Brazil | À vérifier |
| vormatrogineOpen Label Extension Clinical Trial of Vormatrigine in Adult Patients with Epilepsy | Épilepsie | Phase 3 | À vérifier | United States, Brazil, Germany, Italy, Poland, Spain | À vérifier |
| 1.0mg/kg/day PRAX-562A Phase 3, Randomized, Multi-Center, Double-Blind, Placebo-Controlled Clinical Trial to Evaluate the Efficacy, Safety, Tolerability, and Pharmacokinetics of Relutrigine in Participants with Developmental and Epileptic Encephalopathies Followed by an Open-Label Extension | Épilepsie | Phase 3 | À vérifier | United States, Australia, Brazil | À vérifier |
| 1mg elsunersenA Multi-Center, Single-Arm Clinical Trial to Investigate the Efficacy and Safety of Elsunersen in Pediatric Participants with Early Onset SCN2A Developmental and Epileptic Encephalopathy | Épilepsie | Phase 3 | À vérifier | United States, Brazil, Germany, Italy | À vérifier |
| 40 mg/day vormatrogine for 12 weeksA multicenter, double-blind, randomized, placebo-controlled clinical trial to evaluate the efficacy and safety of vormatrigine in adults with focal seizures (POWER2) | Épilepsie | Phase 3 | À vérifier | United States | À vérifier |
| PRAX-222 - Initial DoseThe goal of this trial is to learn about the effect of PRAX-222 in pediatric participants with early onset SCN2A developmental and epileptic encephalopathy (DEE), aged 2 to 18 years. | Épilepsie | Phase 1/2 | À vérifier | United States, Brazil | À vérifier |
| vormatrogineOpen Label Extension Clinical Trial of Vormatrigine in Adult Patients with Epilepsy | Épilepsie | Phase 3 | À vérifier | United States, Brazil, Germany, Italy, Poland, Spain | À vérifier |
Essais cliniques
5| Molécule | Indication / population | Phase | NCT | Titre | Statut |
|---|---|---|---|---|---|
| vormatrogine | Épilepsie | Phase 3 | NCT07287163 | Clinical Trial of Vormatrigine in Adult Patients With Epilepsy | ENROLLING_BY_INVITATION |
| PRAX-222 - Initial Dose | Épilepsie | Phase 1/2 | NCT05737784 | A Clinical Trial of PRAX-222 in Pediatric Participants With Early Onset SCN2A Developmental and Epileptic Encephalopathy | ACTIVE_NOT_RECRUITING |
| 40 mg/day vormatrogine for 12 weeks | Épilepsie | Phase 3 | NCT07505004 | POWER2 — Randomized Clinical Trial Evaluating the Efficacy and Safety of Vormatrigine in Adults With Focal Seizures | ACTIVE_NOT_RECRUITING |
| 1mg elsunersen | Épilepsie | Phase 3 | NCT07019922 | A Clinical Trial of Elsunersen in Pediatric SCN2A-DEE to Assess Efficacy and Safety | RECRUITING |
| 1.0mg/kg/day PRAX-562 | Épilepsie | Phase 3 | NCT07010471 | EMERALD — A Clinical Trial for Participants With DEE to Assess Efficacy, Safety, Tolerability, and PK of Relutrigine | ACTIVE_NOT_RECRUITING |
Publications
8| Molécule | Indication / population | Titre | Journal | Date |
|---|---|---|---|---|
| 20 mg/day vormatrogine for 12 weeks | First-Trimester Zinc Supplementation Reduces Preeclampsia Incidence in Chronic Hypertensive Pregnancies: A Single-Center Retrospective Observational Study. | Biological trace element research | ||
| 20 mg/day vormatrogine for 12 weeks | Efficacy and safety of combining microneedling with oral doxycycline for the treatment of rosacea: a retrospective comparative cohort study. | The Journal of dermatological treatment | ||
| 30 mg/day vormatrogine for 12 weeks | Efficacy and safety of semaglutide injection in Indian patients with type 2 diabetes mellitus inadequately controlled on metformin: A phase 3, randomized, active-controlled, multicenter, non-inferiority trial (WIN-IND study). | Metabolism open | ||
| 30 mg/day vormatrogine for 12 weeks | A prospective, randomized, double-blind, placebo-controlled, multicenter study of thiamin plus folic acid in the treatment of cognitive impairment in patients undergoing maintenance hemodialysis. | Renal failure | ||
| 30 mg/day vormatrogine for 12 weeks | 12‑weeks fisetin supplementation and interval resistance with aerobic training: changes in Maresin‑1 and inflammatory markers in men with obesity: a randomized controlled trial. | Journal of the International Society of Sports Nutrition | ||
| 40 mg/day vormatrogine for 12 weeks | Astaxanthin Supplementation Lowers Respiratory Exchange Ratio During Submaximal Cycling in Females: A Randomized, Double-Blind, Placebo-Controlled Crossover Trial. | Journal of dietary supplements | ||
| 40 mg/day vormatrogine for 12 weeks | Tetrandrine injection for preventing radiation-induced lung injury in patients with locally advanced esophageal squamous cell carcinoma: a randomized controlled trial protocol. | Frontiers in oncology | ||
| 40 mg/day vormatrogine for 12 weeks | Cognitive improvement by daily intake of coffee cherry pulp extract from Coffea canephora var. Robusta in a Japanese population: A randomized, placebo-controlled, double-blind, parallel-group comparison trial. | Complementary therapies in medicine |